For US Residents Only
Understanding Metastatic Castration-Resistant Prostate Cancer
PLUVICTO is used for the treatment of PSMA-positive metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer (mCRPC) is a type of prostate cancer that has spread to other parts of your body and is no longer responding to hormone treatment that lowers testosterone
- PSMA (prostate-specific membrane antigen) is a biomarker that sits on the outside of prostate cancer cells and is detected by a PSMA positron emission tomography (PET) scan
If your prostate cancer cells have an abundance of PSMA, it means your mCRPC is PSMA positive (PSMA+). PSMA+ cancer cells can be targeted with PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan).
Noncancerous PSMA+ cells and other surrounding cells will also will be impacted.
You can find out if your prostate cancer is PSMA+ by having a PSMA PET scan
Ask your doctor about treating your metastatic prostate cancer with PLUVICTO.